Humanised antibodies
CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions ( 6, 23 ) and/or ( 24, 48 ) and/or ( 49, 71 ) and/or ( 73, 75 ) and/or ( 76 ) and/or ( 78 ) and ( 88 ) and/or ( 91 ). The...
Saved in:
Main Authors | , , |
---|---|
Format | Patent |
Language | English |
Published |
09.06.2005
|
Edition | 7 |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions ( 6, 23 ) and/or ( 24, 48 ) and/or ( 49, 71 ) and/or ( 73, 75 ) and/or ( 76 ) and/or ( 78 ) and ( 88 ) and/or ( 91 ). The CDR-grafted light chains comprise donor residues at at least one of positions ( 1 ) and/or ( 3 ) and ( 46 ) and/or ( 47 ) or at at least one of positions ( 46,48, 58 ) and ( 71 ). The CDR-grafted antibodies are preferably humanised antibodies, having non human, e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies. |
---|---|
Bibliography: | Application Number: US20040937971 |